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Some cancers are associated with viral
infections, one of the most important
being cervical carcinoma for which hu-
man papillomavirus (HPV) is a major
risk factor. Most HPV infections do not
lead to cancer, but sometimes integra-
tion of viral DNA into a cell chromo-
some occurs, resulting in interruption
of the viral regulatory gene E2 and con-
tinued production of the oncoproteins
E6 and E7. This extends the life span
of the host epithelial cell and favours
the accumulation of further genetic
changes which lead to the loss of dif-
ferentiated characteristics and progres-
sion towards becoming a cancer cell.
Our research is aimed at interfering
with this process. Here, we will first
summarise certain aspects of HPV in-
fection, then consider the role of the
virus in cancer.
The HPVs are a family of small DNA
viruses which infect epithelial cells of
the skin or mucosa (reviewed in {1}).
Among the HPVs infecting genital mu-
cosa, a certain number - the so-called
high-risk viruses, including notably
HPV16 and HPV18 - induce lesions
with an increased risk of progressing to
cervical cancer. The circular viral
genome of approximately 8 kb encodes
two classes of proteins (see Fig. 1): the
early (E) proteins which establish a per-
missive cellular environment and take
part in viral replication, and the late (L)
proteins which form the viral capsid.
Papillomavirus replication linked to
keratinocyte differentiation
HPVs are thought to infect ker-
atinocytes of the basal layer of an epi-
thelium. In these cells there is a low lev-
el of E gene expression and the episo-
mal viral DNA replicates, we found, in
step with cellular DNA replication.
Subsequent viral production is inti-
mately linked to the differentiation of
the infected keratinocyte. As the cell
terminally differentiates and moves to-
wards the outer edge of the epithelium,
viral DNA is amplified to high copy
number, capsid proteins are synthe-
sised and progeny viruses assembled.
There is therefore a central paradox in
HPV’s requirements for replication: on
one hand the terminally differentiating
keratinocyte exits from the cell cycle
and no longer synthesises DNA, but on
the other, the virus needs active cellu-
lar DNA replication machinery to en-
able its own DNA to replicate. To re-
solve this paradox is the function of the
HPV E6 and E7 proteins (for a recent
review see {2}, and references there-
in). Normally entry of a cell into the S-
phase of the cell cycle is regulated by
cyclin-dependent kinase activities
which phosphorylate the retinoblas-
toma tumour suppressor protein (pRB)
which in turn releases active transcrip-
tion factors needed for the expression
of S-phase specific genes. High-risk
HPV E7 can intervene at several points
to promote this process, by interactions
with pRB, cyclins and kinase in-
hibitors. HPV E6 binds the p53 tumour
suppressor protein and targets it for
degradation. Normally p53 prevents a
cell with DNA damage from entering
S-phase, and is also involved in path-
ways leading to programmed cell
death. Thus E6 and E7 act together to
maintain the virus-infected ker-
atinocyte in a state which allows the
synthesis of DNA.
In HPV-containing cancer cells this vi-
ral growth cycle seems to have been in-
terrupted. For reasons which are not yet
clear the normally episomal viral DNA
integrates into a host cell chromosome
(Fig. 2). Integration is generally such
that the viral E6 and E7 genes are in-
tact and expressed, while other early
genes, notably E2, are disrupted. This
process of E2 gene disruption has been
reported to correlate with poor disease
prognosis {3}. These observations sug-
gested that the HPVE2 protein behaves
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Fig. 1. Current understanding of HPV gene expression linked to epithelial cell differentia-
tion. The normally circular HPV16 genome is shown in linear form.
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like a natural tumour suppressor whose
presence is incompatible with contin-
ued cell proliferation. E2 can function
as a transcription factor for the HPV
promoter region, and so control ex-
pression of the E6 and E7 genes. How-
ever, E2 has effects on cells which are
independent of this {4, 5}. We are
therefore testing the effects of E2 on
cell division, both in human ker-
atinocytes, the normal hosts of HPV,
and in yeast cells where mechanisms of
effects on the cell cycle are easier to
analyse.
Papillomavirus E2 protein delays the
entry of cells into mitosis
We found, in collaboration with N.
Fournier and V. Simanis of ISREC, that
expression of the HPV16 E2 protein in
the fission yeast Schizosaccharomyces
pombe retards the G2-M transition, by
delaying activation of Cdc2 kinase. In
contrast, S-phase progression, and
commitment to cell division in late G1
are not affected. The delay is indepen-
dent of the transcriptional trans-activa-
tion function of E2, and does not result
from E2 binding to DNA and mimick-
ing DNA damage. Increased expres-
sion of E2 also delays mitotic initiation
in mammalian cells as judged by flow
cytometric analysis. S. pombe may thus
provide a simple model for the analy-
sis of E2 function and we are now look-
ing into the mechanisms of E2’s effect
on the cell cycle.
What purpose could the anti-prolifera-
tive function of E2 play in the HPVlife-
cycle? We mentioned above that the ex-
pression of viral genes is tightly linked
to the differentiation state of the in-
fected cell as it migrates to the outer
layers of the stratified epithelium. Al-
though at early times after infection the
viral E6 and E7 genes cause the differ-
entiating cell to re-enter the cell cycle
and allow the virus to replicate its
DNA, while suppressing p53-mediat-
ed apoptosis, the late genes L1 and L2,
which encode the viral capsid proteins,
can only be expressed as the host cell
reaches the final stages of differentia-
tion. It therefore appears that prolifer-
ation of the infected cell must be re-
stricted to allow it to continue its dif-
ferentiation program. This role may be
fulfilled by the anti-proliferative func-
tion of the E2 protein. This is also con-
sistent with the observation that E2
function is lost in HPV-induced tu-
mours. Treatment based on putting E2
back into cervical cancer cells is an in-
teresting possibility for the future, but
has not been tested yet.
Papillomavirus-like particles
and vaccination
There is good reason to believe that the
cellular immune system helps control
HPVinfection and disease. Patients un-
dergoing immunosuppressive treat-
ments, or infected with HIV, or with an
inborn defect in immunity are all more
susceptible to the development of
HPV-induced lesions. It would be very
desirable to have HPV viral particles
for use in vaccines. However, HPVs
cannot be easily propagated in cell cul-
ture because, as pointed out already, vi-
ral replication depends on the differen-
tiation of epithelial cells. Therefore an
important goal of several research
groups, including our own, has been to
produce artificial virus-like particles
(VLPs) by synthesising the viral cap-
sid proteins L1 and L2 in recombinant
baculovirus or vaccinia virus-based ex-
pression systems {6, 7}. To test whether
DNA could be incorporated into such
VLPs, we used recombinant vaccinia
viruses expressing the HPV18 L1 and
L2 proteins to infect human 293-T cells
carrying an episomal plasmid DNA
with an SV40 origin of replication and
the ß-galactosidase gene as marker
(Fig. 3). The results showed that this
non-papillomavirus DNA can be pack-
aged into HPV VLPs. These particles
are infectious and may provide a much
needed reagent for infectivity and vac-
cination studies with HPV18. Clinical
trials on the effectiveness of VLPs as
vaccines are already under way in Eu-
rope and the USA {8}. 
Fig. 2. Integration of HPV DNA into the cell DNA in cervical cancer.
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It is not clear that vaccination would be
useful against existing lesions so other
approaches are being sought. One of
these involves retinoids. Retinoic acid
reduces expression of the HPV onco-
proteins E6 and E7, and in addition has
marked effects on epithelial cell dif-
ferentation. We are studying the mech-
anisms of retinoic acid’s effects on the
expression of E6 and E7 in cervical tu-
mour cells and the accompanying
changes in cell cycle progression. We
showed that transcription of the inte-
grated HPV18 E6 and E7 oncogenes in
C4-1 cervical tumour cells is reduced
by retinoic acid, and in vivo footprint-
ing suggested that this may be due to
reduced occupation of AP1 sites in the
promoter. The possibility of using
retinoids, in the presence or absence of
other drugs, against HPV-induced le-
sions is being explored {9}. 
Anti-proliferative effects of the
adeno-associated virus Rep protein
Avery different approach makes use of
a virus which would counteract HPV. 
In contrast to HPV, the adeno-associat-
ed virus (AAV) inhibits tumorigenesis
in experimental systems, and infection
by AAVwas reported to be less frequent
than average in women with cervical
carcinoma {10}. We are therefore very
interested in the interactions between
AAV and HPV in keratinocytes and the
effects of the AAV regulatory protein,
Rep, on the cell division cycle.
The anti-oncogenic effects of AAV are
very likely mediated, at least in part, by
the viral regulatory protein Rep. Rep is
a multi-functional protein with proper-
ties including site-specific DNA bind-
ing and cleavage, helicase and ATPase
activity (see {11} and references there-
in). We are investigating the possible
oncosuppressive activity of the Rep
protein by introducing a recombinant
retroviral vector expressing Rep into
different cell types. Rep was found to
have a strong anti-proliferative effect.
Flow cytometric analysis showed that
primary rat fibroblasts expressing Rep
accumulate in G1 and G2 with fewer
cells in the S-phase of the cell cycle. 
To test whether the block imposed by
Rep can be overcome by proliferative
signals we used cell populations over-
expressing oncogenes including adeno-
virus E1a, v-H-ras, c-myc and HPV E6
and E7, alone or in combinations. None
of these oncogenic stimuli could antag-
onise Rep’s anti-proliferative activity.
On the contrary, some of these cells
were even more sensitive to Rep, poss-
sibly due to induction of apoptosis.
Papillomavirus genes contribute
helper functions for adeno-
associated virus replication
AAV is a defective virus and needs a
helper for its replication. There is evi-
dence that HPV and AAV can co-exist
in the cervical epithelium {12}. If HPV
could function as helper it would lead
to the production of AAV proteins in-
cluding Rep. To test if this is the case,
we transfected into human ker-
atinocytes an infectious clone of AAV
DNA along with plasmids encoding
various HPV16 proteins and then test-
ed whether AAV was produced.
In the absence of helper effect, only very
little or no AAVwas detected. Co-trans-
fection of the E2 gene gave an increase
of more than 100 fold. The HPV16 E1
gene was also able to increase AAVpro-
duction, whereas E4 had no effect. We
conclude that HPV16 gene products in-
cluding notably E2 and E1 are able to
stimulate AAVreplication in these cells.
This finding suggests that HPV belongs
to the group of viruses which provide
helper functions allowing AAV replica-
tion. In view of the dramatic effects
which the AAVRep protein has on cells,
it clarifies how AAV may interfere with
HPV infection and so hinder cervical
cancer development.
Knowledge of how AAV-coded pro-
teins achieve their effects on cells
should enhance our understanding of
HPV-mediated cervical disease and is
a potential key to developing therapeu-
tic strategies.
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Fig. 3. Infectious human papillomavirus containing totally foreign DNA, made using the pSVβ
plasmid and recombinant vaccinia virus-encoded HPV L1 and L2 proteins. In the electron
micrograph of HPV18 virus-like particles, their diameter is ~55nm. The blue coloured C127
cells indicate β-galactosidase activity following infection (from reference 7).
